Biosimilar Focus NeuClone is a clinical stage biopharma dedicated to developing and commercialising biosimilars, presenting multiple near-term opportunities across oncology, autoimmune, and other therapeutic areas in global markets.

Early-stage Validation The Right From the Start approach emphasizes early and continual confirmation of biosimilarity, suggesting a potential sales advantage with faster regulatory confidence and smoother market access for partners.

Strategic Partnerships Past collaborations with Serum Institute and joint development for ten biosimilars indicate a readiness for co-development and manufacturing partnerships, offering avenues for contract development, manufacturing, and tech transfer deals.

Global Expansion Fit NeuClone targets global registration and scalable biosimilar pipelines, aligning with distributors, regional launch partners, and CROs to accelerate market entry in new and established territories.

Small Team, Agile With a lean headcount and a focused pipeline, NeuClone presents a nimble partner profile for boutique biotech investors and specialty manufacturers seeking rapid collaboration, licensing, or off-take agreements.